1.	Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Phase: Phase II, Phase I Type: Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02015, S0905, CDR0000665415, U10CA032102, SWOG-S0905, NCT01064648
2.	Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 100138, 10-C-0138, NCT01143545
3.	Treating Cancer With Anti-mesothelin Modified Lymphocytes Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120111, 12-C-0111, NCT01583686
4.	An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TL139204, NCT00685204
5.	Trimodal Lung-Sparing Treatment of Pleural Mesothelioma Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: AAAB9658 (A6), NCT00859495
6.	Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AAAD4868, NCT00996385
7.	Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 19 and over Sponsor: Other Protocol IDs: F090917002 (UAB 0901), UAB 0901, NCT01204203
8.	Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 12-0032, NCI-2012-00332, NCT01592383
9.	Sunitinib and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-03112, 050909, U01CA132194, CINJ-050801, 050801, 0220080281, NCT00813423
10.	Intrapleural Gene Transfer for Pleural Mesothelioma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: UPCC 18508, P01CA066726, NCT01212367
11.	Tumor Cell Vaccines With ISCOMATRIX(Trademark) Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110041, 11-C-0041, NCT01258868
12.	SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110160, 11-C-0160, NCT01362790
13.	Study of ABT-700 in Subjects With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M12-375, NCT01472016
14.	Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-169, NCT01766739
15.	Combination Gene Transfer and Chemotherapy Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 02510, NCT01119664
16.	Amatuximab for High Mesothelin Cancers Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110212, 11-C-0212, NCT01413451